Chat GPT also supports new drug development… OpenAI and Moderna team up

OpenAI and Moderna have joined forces to utilize artificial intelligence (AI) in new drug development.
Moderna announced on the same day that it had formed a partnership to develop an mRNA vaccine. Moderna is based on OpenAI's AI large language model (LLM) GPT.
The plan is to automate the process required for mRNA vaccine development through the chatbot "Chat GPT Enterprise."
mRNA is the genetic material used to synthesize proteins outside the cell nucleus.
Using mRNA makes it possible to develop a vaccine more quickly than with conventional methods. The COVID-19 vaccine was developed using mRNA.
Moderna hopes that by using Chat GPT Enterprise, it will be able to further speed up the development of mRNA vaccines.
The goal is to develop 15 types of mRNA vaccines within five years. Specifically, the company plans to use chat GPT Enterprise for clinical trial design, enzyme structure prediction, and regulatory agency responses.
OpenAI has also decided to support Moderna's use of chat GPT Enterprise through weekly strategy meetings and Slack channels.
Moderna CEO Stephane Bancel said, "Moderna believes Chat GPT and open AI will change the world.
"We are examining all business processes, from legal to research, manufacturing and sales, and thinking about how to redesign them with AI," he said.